<DOC>
	<DOC>NCT02398526</DOC>
	<brief_summary>This observational prospective single arm cohort study is designed to assess pain and bone pain related quality of life of metastatic Castration Resistant Prostate Cancer (mCRPC) patients receiving Radium-223 in a real life nuclear medicine practice setting. In addition, overall survival, time to next tumor treatment (TTNT), time to first symptomatic skeletal event (SSE), course of blood counts, and safety will be assessed.</brief_summary>
	<brief_title>Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms, Castration-Resistant</mesh_term>
	<mesh_term>Succinylcholine</mesh_term>
	<mesh_term>Radium Ra 223 dichloride</mesh_term>
	<criteria>Adult male patients diagnosed with CRPC with symptomatic bone metastases without known visceral metastases Decision to initiate treatment with Radium223 was made as per investigator's routine treatment practice Patients participating in an investigational program with interventions outside of routine clinical practice or participating in another observational study with Xofigo</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Observational study</keyword>
	<keyword>Bone metastases</keyword>
	<keyword>Hormone Refractory Prostatic Cancer</keyword>
	<keyword>Xofigo</keyword>
	<keyword>Radium-223</keyword>
</DOC>